Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

Slides:

Advertisements

Similar presentations

Changes in graft function in long term renal transplant recipients – analysis by CKD stage and recipient characteristics U.P.Udayaraj, D.Ansell, R.Steenkamp,

Advertisements

SYMPHONY: Results at 12 Months. Daclizumab Low dose CsA MMF Steroids B 50–100 ng/ml Low dose SRL D MMF Steroids Daclizumab 4-8 ng/ml Low dose TAC MMF.

The European experience with protocol biopsies Ian Roberts Oxford, UK Oxford Pathology.

1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

D. Serón Nephrology Department Hospital Vall d’Hebron Barcelona Interpretation of sequential protocol biopsies in terms of prognosis and clinical implications.

Who is the best donor for a related HLA haplotype-mismatched transplant? by Yu Wang, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Dai-Hong Liu, Xiao-Hui Zhang,

Section 1: CKD Epidemiology

The LIVES Sub-analysis

Careggi University Hospital–

Immunological risk assessment: The key to individualized immunosuppression after kidney transplantation Johann Pratschke, Duska Dragun, Ingeborg A. Hauser,

Living unrelated donor kidney transplantation

Number of transplants, by donor type figure 8.1

Volume 60, Issue 1, Pages (July 2001)

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

Effects of MMF treatment in patients with SLE

The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate-

Incidence of nonskin cancers at five years

Progression of CKD with ADMA levels above and below the median

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

Histomorphology in a case of mixed (cellular and humoral) acute kidney allograft rejection (patient 10). Histomorphology in a case of mixed (cellular and.

Risk factors in deceased-donor transplants Risk factor 1988

Impact of Cognitive Function Change on Mortality in Renal Transplant and End-Stage Renal Disease Patients Sharma et al. Am J Nephrol 2016;44: (DOI: / )

End point Valsartan, n (%) Placebo, n (%) Hazard ratio (95% CI) P*

Variable Pretreatment Posttreatment P GFR (mL/min) 115±18 102±14 NS

Mean eGFR among survivors after CABG surgery vs all-cause deaths

TNT post hoc analysis: Improvement between baseline and final visit in estimated GFR by treatment group End point 10-mg atorvastatin 80-mg atorvastatin.

Overall survival from enrolment according to operating rule and scenario of organ scarcity for a) scenario R96 (i.e. 96 organs for 100 virtual patients.

Forest plot of the HRs for DOACs vs warfarin for (A) new or recurrent VTE and (B) major bleeding based on the published subanalyses of the patients with.

Volume 82, Issue 5, Pages (September 2012)

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

S. Sagedal, A. Hartmann, H. Rollag Clinical Microbiology and Infection

Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease.

The incidence of all cause graft failure, and death with a functioning graft was higher in patients who received a DCD donor transplant with total donor.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Figure 6 Hypothetical effect of starting therapy for autosomal

Effects of reslizumab on asthma quality of life questionnaire (AQLQ) score in Global Initiative for Asthma (GINA) Step 4 and 5 patients. Effects of reslizumab.

A) Evolution of the yearly mortality rate from year 1 to year 15 of simulation according to the operating rule and to the scenario of organ scarcity. b)

A) Evolution of the proportion of virtual patients (VPs) that died or received a graft while on the high-priority list by year according to the scenario.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Predictors of disease progression in patients with CKD

C.Y. Hsu, J.D. Ordoñez, G.M. Chertow, D. Fan, C.E. McCulloch, A.S. Go

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Anemia as a risk factor for chronic kidney disease

Living unrelated donor kidney transplantation

Patient characteristics: American vs Canadian transplant patients

Mean change from baseline in symptom scales and single-item assessments after 6 weeks of alectinib treatment according to (A) the QLQ-C30 and (B) the QLQ-LC13.

Classification by HtTKV0 and age at HtTKV0 predicts the change in eGFR over time in class 1 patients. Classification by HtTKV0 and age at HtTKV0 predicts.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Overcoming Barriers to Long-Term Graft Survival

(A through C) Mean eGFR during follow-up according to treatment assignment in patients with normoalbuminuria (A), microalbuminuria (B), and macroalbuminuria.

Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:

Volume 60, Issue 1, Pages (July 2001)

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Giuseppe Remuzzi, Carlos Chiurchiu, Piero Ruggenenti

Intrapatient variability in cyclosporine blood levels in renal transplant patients. Intrapatient variability in cyclosporine blood levels in renal transplant.

Volume 64, Issue 4, Pages (October 2003)

Kaplan-Meier estimation of diabetes-related survival curves in patients grouped according to increased 24-h proteinuria (A), the presence of preexisting.

Distribution of patients in the first- or second-year follow-up according to the number of acute exacerbations of chronic obstructive pulmonary disease.

S. Dmitrienko, A. Yu, R. Balshaw, R.J. Shapiro, P.A. Keown

Change in total kidney volume and renal function over 3 years of tolvaptan compared with matched control and their correlation for individual subjects.

Plots of average estimated and measured GFR vs

Reduction in mean pulmonary vascular resistance (PVR) in 37 subjects following acute sildenafil administration to ongoing bosentan therapy in the COMPASS-1.

Bias with estimated GFR (eGFR) by age (years).

Prevalence of acute myocardial infarction (AMI) or other cardiovascular events (CVEs) according to a) Pneumonia Severity Index (PSI) risk classes and b)

Renal hemodynamics. Renal hemodynamics. GFR (A), effective renal plasma flow (ERPF; B), and filtration fraction (FF; C) in patients with diabetes and with.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Perception of indications for referral to a nephrologist among internal medicine residents according to the postgraduate year (PGY). Perception of indications.

Presentation transcript:

GFR (mL/min per 1.73 m2) in high-risk renal transplant patients according to treatment Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor SRL + CsA 56.5 43.3 <0.001 SRL 55.3 57.5 0.273 Second transplant 55.5 38.9 0.011 52.4 46.7 0.239 Donor age >50 years 49.5 35.0 49.0 46.2 0.326 HLA mismatch ≥4 56.3 41.7 54.6 58.5 0.215 Acute rejection 46.6 27.1 0.012 41.6 0.099 Proteinuria 52.6 35.1 0.001 53.8 52.1 0.653 Legendre C et al. 12th Congress of the European Society for Organ Transplantation; October 15-19, 2005; Geneva, Switzerland.